Yichang Humanwell Pharmaceutical's Class 1 new drug RFUS-949 tablets approved for clinical trials
Time：
2025-06-06
Recently, Yichang Renfu Pharmaceutical Co., Ltd. received a "Notice of Approval for Drug Clinical Trials" issued by the National Medical Products Administration, approving the clinical trial of RFUS-949 tablets for the treatment of acute and chronic pain. This product is a new molecular entity drug developed by Yichang Renfu, classified as Class 1 chemical drug for registration, and there are no similar products approved for marketing in China.
Recently, Yichang Renfu Pharmaceutical Co., Ltd. received a "Notice of Approval for Drug Clinical Trials" issued by the National Medical Products Administration, approving the clinical trial of RFUS-949 tablets for the treatment of acute and chronic pain. This product is a new molecular entity drug developed by Yichang Renfu, classified as Class 1 chemical drug for registration, and there are no similar products approved for marketing in China.
RFUS-949 is a specific antagonist of the Sigma-1 receptor, mainly exerting its analgesic effect by antagonizing the Sigma-1 receptor. Non-clinical studies have shown that RFUS-949 has significant analgesic activity, high oral bioavailability, and no significant toxic reactions were observed, indicating good safety.
The development of RFUS-949 tablets is an important strategic move by Yichang Renfu in the research and development of anesthetic and analgesic drugs. After receiving the above-mentioned Notice of Approval for Drug Clinical Trials, the company will start the relevant work, and after completing the clinical research, it will submit an application for marketing authorization and apply for production and marketing.
Tags:
Related News
ABOUT US
CONTACT
Add：66 Tianjiahe Avenue, Baiyang Town, Baiyang,Industrial Park, High-tech Zone,Yichang City, Hubei Province, China.
Tel：+86-717-4065884 +86-717-4065888
E-mail：yctr@renfu.com.cn
Copyright © 2024 YICHANG TIANRUI BIOPHARM CO., LTD All Rights Reserved.